ProMIS Neurosciences Inc (ProMIS) is a clinical-stage biotechnology company that focuses on the discovery and development of therapeutic antibodies. The company specializes in medical conditions like multiple system atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease that are marked by abnormal, misfolded proteins. Its PMN310, a monoclonal antibody (mAb), designated as its first lead product for development in Alzheimer's disease (AD). The company utilizes its patented technology platform to generate therapeutic antibody candidates that selectively target toxic forms of proteins without interfering with the functions of the healthy proteins. ProMIS is headquartered in Toronto, Ontario, Canada.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company ProMIS Neurosciences Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
ProMIS Neurosciences Inc Company Overview
ProMIS Neurosciences Inc Company Snapshot
ProMIS Neurosciences Inc Pipeline Products and Ongoing Clinical Trials Overview
ProMIS Neurosciences Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
ProMIS Neurosciences Inc, Recent Developments
Aug 06, 2024: ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
Jun 30, 2023: ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
Jun 29, 2023: ProMIS Annual Meeting of Shareholders on June 29, 2023
Dec 16, 2021: ProMIS Neurosciences Issues Chairman’s Memorandum
Oct 07, 2021: ProMIS Neurosciences Announces Special Shareholder Meeting
May 25, 2021: ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
Feb 02, 2021: ProMIS Neurosciences offers perspectives on recent progress in the Alzheimer’s/amyloid field
Jan 12, 2021: ProMIS Neurosciences announces strategic priorities for 2021
Jun 17, 2020: ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19
May 19, 2020: ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
ProMIS Neurosciences Inc Pipeline Products and Ongoing Clinical Trials Overview
ProMIS Neurosciences Inc Pipeline Products by Equipment Type
ProMIS Neurosciences Inc Pipeline Products by Indication
ProMIS Neurosciences Inc, Key Facts
ProMIS Neurosciences Inc, Major Products and Services
ProMIS Neurosciences Inc Number of Pipeline Products by Development Stage
ProMIS Neurosciences Inc Pipeline Products Summary by Development Stage
Antibody Test - COVID-19 - Product Status
Antibody Test - COVID-19 - Product Description
Companion Diagnostic Test - ALS - Product Status
Companion Diagnostic Test - ALS - Product Description
Companion Diagnostic Test - Alzheimer's Disease - Product Status
Companion Diagnostic Test - Alzheimer's Disease - Product Description
EP-vCJD Assay - Product Status
EP-vCJD Assay - Product Description
NfL Test - Alzheimer's Disease - Product Status
NfL Test - Alzheimer's Disease - Product Description
P-tau181 Test - Alzheimer's Disease - Product Status
P-tau181 Test - Alzheimer's Disease - Product Description
ProMIS - Cancer - Product Status
ProMIS - Cancer - Product Description
Screening Test - Liver Cancer - Product Status
Screening Test - Liver Cancer - Product Description
Serology Test - Immunity Assessment - Product Status
Serology Test - Immunity Assessment - Product Description